Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-23

Clinical Trial Update: Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating combination therapy with lanreotide Autogel and pegvisomant in acromegaly has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lanreotide Autogel (lanreotide)
  • Pegvisomant (pegvisomant)

Snippet

Sponsor: Ipsen | Conditions: Acromegaly | Phase 3 | Status: COMPLETED | Results posted: 2018-07-23